lilly glp-1 drug Eli Lilly's $1 Trillion Boom: Inside Dave Ricks' Weight-Loss Bet Lilly lowers self-pay prices of

This has potential to alleviate supply shortages currently plaguing the class, and may provide an opportunity for Lilly to bring a lower-cost option to market, though Lillys pricing strategy for orforglipron is unknown and likely to be dependent upon clinical results

Your best choice depends on your budget, tolerance for side effects, and how quickly you want to see results

LENHOFF H et al

Bertoni, M., Kiefer, F., Biasini, M., Bordoli, L

For obesity therapeutics, Phase 3 trials are especially important because regulators want to see: Long-term weight loss sustainability Cardiovascular safety Real-world tolerability Effects on obesity-related conditions such as diabetes, sleep apnea, and osteoarthritis Retatrutides Phase 3 program, called TRIUMPH , includes multiple large-scale studies across different patient populations